Presentations

Presentations

Presentations

PRESENTATIONS

Date Title Documents

“Once every 4 weeks - 2 mg/kg of pegunigalsidase alfa for treating Fabry disease; Preliminary results of a Phase 3 study” -- Oral Presentation by Mr. Myrl D. Holida, PA, at the 15th Annual WORLDSymposiumTM 2019

Analysis of the baseline characteristics of Fabry disease patients screened for the pegunigalsidase alfa phase III BALANCE study” -- Poster Presentation by Prof. David Warnock at the 15th Annual WORLDSymposiumTM 2019

“Once every 4 weeks – 2 mg/kg of pegunigalsidase alfa for treating Fabry disease; Preliminary results of a phase 3 study” -- Poster Presentation by Mr. Myrl D. Holida, PA, at the 15th Annual WORLDSymposiumTM 2019

"Pegunigalsidase alfa for the Treatment of Fabry Disease - Phase III Open Label, Switch-Over Study from agalsidase alfa – Preliminary Results" -- Poster Presentation by Prof. Ales Linhart at the 15th Annual WORLDSymposiumTM 2019

Protalix Biotherapeutics Corporate Update January 2019

"Pegunigalsidase alfa -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease: Preliminary Results from the Phase III Bridge Study" - Presentation by Dr. Michael L. West at the 1st Canadian Symposium on Lysosomal Diseases 2018

"Pegunigalsidase alfa -- Novel Enzyme Replacement Therapy for the Treatment of Patients with Fabry Disease: Preliminary Results from the Phase III Bridge Study" - Presentation by Dr. Michael L. West at the 1st Canadian Symposium on Lysosomal Diseases 2018

"Novel Orally Administered Recombinant Anti-TNF alpha Fusion Protein for the Treatment of Ulcerative Colitis: Phase 2a Clinical Trial Showing Promising Results" -- Presentation by Dr. Yaron Ilan at the Digestive Disease Week® (DDW) 2018 Annual Meeting

"Novel Orally Administered Recombinant Anti-TNF alpha Fusion Protein for the Treatment of Ulcerative Colitis: Phase 2a Clinical Trial Showing Promising Results" -- Presentation by Dr. Yaron Ilan at the Digestive Disease Week® (DDW) 2018 Annual Meeting

"Progression of Nephropathy in Fabry Patients Receiving Enzyme Replacement Therapy (ERT); Relation to Anti-Drug Antibody (ADA) Status and Proteinuria" -- Poster Presentation by Dr. David Warnock at the at the 55th ERA-EDTA Congress, May 2018

"Progression of Nephropathy in Fabry Patients Receiving Enzyme Replacement Therapy (ERT); Relation to Anti-Drug Antibody (ADA) Status and Proteinuria" -- Poster Presentation by Dr. David Warnock at the at the 55th ERA-EDTA Congress, May 2018

"Pegunigalsidase alfa, a Novel PEGylated ERT for Fabry Disease - Two Years Safety and Efficacy Follow Up" -- Poster Presentation by Dr. Derralynn Hughes at the 14th Annual WORLDSymposium(TM) 2018

"Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease" -- Presentation by Dr. David G. Warnock at the 14th Annual WORLDSymposium(TM) 2018

"Enhanced pharmacokinetics profile of pegunigalsidase alfa (PRX-102) supports once-monthly 2mg/kg dosing for the treatment of Fabry disease" -- Poster Presentation by Dr. David G. Warnock at the 14th Annual WORLDSymposium(TM) 2018